Thompson Street Capital Partners, a private equity firm based in St. Louis, completed the investment in Sabai Global, a Chesterfield, MO based provider of regulatory review and biosafety consulting services to pharmaceutical sponsors, CROs, academic health systems, and clinical research site networks. Financial terms were not disclosed. "Our team has worked hard to identify an asset that serves the rapidly growing cell and gene therapy market, and was extremely pleased to find one led by a CEO as passionate as Chris in the St. Louis area. We are proud to support Sabai’s continued growth as they help bring the most cutting-edge, life-saving treatments to market in an efficient, safe, and ethical manner," Matt Scherrer, TSCP Managing Director.